SHAWN WARREN: Open Payments
NPI 1528610532 · KAYSVILLE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$322 in 15 payments from 7 companies in 2025. Trend: 2023 $499 · 2024 $325 · 2025 $322
Food & beverage: $322
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $76 |
| ABBVIE INC. | 4 | $70 |
| Neurocrine BioSciences, Inc. | 2 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: INGREZZA, VRAYLAR, LYBALVI, CAPLYTA, TRINTELLIX, ARISTADA, Auvelity, COBENFY.
Industry payments across UT — which companies pay providers there.
